Literature DB >> 29543959

Single-Stage Mastoid Obliteration in Cholesteatoma Surgery and Recurrent and Residual Disease Rates: A Systematic Review.

Hylke F E van der Toom1, Marc P van der Schroeff1, Robert J Pauw1.   

Abstract

IMPORTANCE: The ideal surgical treatment of cholesteatoma has been subject to discussion for years because both traditional surgical techniques (canal wall down [CWD] and canal wall up [CWU] tympanoplasty) have their own advantages and disadvantages. A more recently propagated surgical approach, to combine the CWD or CWU tympanoplasty technique with obliteration of the mastoid and epitympanum, is showing promising results.
OBJECTIVE: To systematically review the literature on recurrent and residual cholesteatoma rates after single-stage CWU and CWD tympanoplasty with mastoid obliteration. EVIDENCE REVIEW: A systematic search of literature was performed to identify relevant publications in multiple electronic databases. The initial search was conducted in December 2016 and was updated in July 2017. Each study was reviewed by 2 independent reviewers on predetermined eligibility criteria. The methodological quality was determined using the methodological index for nonrandomized studies (MINORS) scale, and the relevance to the current topic was determined using a 4-criterion checklist.
FINDINGS: The searches identified a total of 336 potentially relevant publications; 190 articles were excluded based on title and abstract. The full-text articles of the remaining 146 citations were assessed for eligibility, resulting in 22 articles. After assessing these remaining articles for methodological quality and relevance to the current topic, another 8 studies were excluded, and a total of 13 studies (1534 patients) were included. Of the 1534 patients who underwent CWD or CWU tympanoplasty with mastoid obliteration, the rate of recurrent disease was 4.6%, and the rate of residual disease was 5.4%. In CWU tympanoplasty with mastoid obliteration, these rates were 0.28% and 4.2%, respectively and in CWD tympanoplasty with mastoid obliteration, 5.9% and 5.8%, respectively. CONCLUSIONS AND RELEVANCE: We show the recurrent and residual disease rates after either CWU or CWD tympanoplasty with mastoid obliteration to be qualitatively similar to, if not better than, previously reported rates of for nonobliterative techniques. In this study, the lowest recurrent and residual rates were reported when combining the CWU tympanoplasty with mastoid obliteration, on average 0.28 and 4.2%, respectively.

Entities:  

Mesh:

Year:  2018        PMID: 29543959     DOI: 10.1001/jamaoto.2017.3401

Source DB:  PubMed          Journal:  JAMA Otolaryngol Head Neck Surg        ISSN: 2168-6181            Impact factor:   6.223


  10 in total

1.  Cholesteatoma surgery in the pediatric population: remaining challenges in the era of mastoid obliteration.

Authors:  Victor J Kroon; Steven W Mes; Pepijn A Borggreven; Rick van de Langenberg; David R Colnot; Jasper J Quak
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-10-08       Impact factor: 3.236

2.  Mastoid obliteration with hydroxyapatite vs. bone pâté in mastoidectomy surgery performed on patients with cholesteatoma and chronic suppurative otitis media: a retrospective analysis.

Authors:  Jantine J Lindeboom; P M W van Kempen; J Buwalda; B O Westerlaken; D A van Zuijlen; S J H Bom; F B van der Beek
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-09-29       Impact factor: 3.236

3.  Antibiotics in mastoid and epitympanic obliteration with S53P4 bioactive glass: A retrospective study.

Authors:  Lauranne Alciato; Daniele Bernardeschi; Valérie Pourcher; Naira Mkrtchyan; Frédéric Tankéré; Olivier Sterkers; Ghizlène Lahlou
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-09-14

4.  Outcomes of a novel alloplastic technique for external auditory canal repair in tympanomastoidectomy.

Authors:  Karissa L LeClair; Sarah Y Bessen; Christiaan A Rees; James E Saunders
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-08-04

5.  Cost-comparison analysis of diffusion weighted magnetic resonance imaging (DWMRI) versus second look surgery for the detection of residual and recurrent cholesteatoma.

Authors:  David L Choi; Michael K Gupta; Ryan Rebello; Jason D Archibald
Journal:  J Otolaryngol Head Neck Surg       Date:  2019-11-07

6.  Recurrence of Cholesteatoma - A Retrospective Study Including 1,006 Patients for More than 33 Years.

Authors:  Patrick Rønde Møller; Christina Nygaard Pedersen; Line R Grosfjeld; Christian E Faber; Bjarki D Djurhuus
Journal:  Int Arch Otorhinolaryngol       Date:  2019-12-20

7.  Evaluation of the SAMEO-ATO surgical classification in a Dutch cohort.

Authors:  Fleur A Ten Tije; Sietze Alkema; Lisa van der Putten; Jan Pieter Koopman; Joeri Buwalda; Sophia E Kramer; Robert Jan Pauw; Paul Merkus
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-06-11       Impact factor: 2.503

8.  Postoperative surgical site infection in cholesteatoma surgery with and without mastoid obliteration, what can we learn?

Authors:  F L J Cals; H F E van der Toom; R M Metselaar; A van Linge; M P van der Schroeff; R J Pauw
Journal:  J Otol       Date:  2021-10-29

Review 9.  The Roles of NOD-like Receptors in Innate Immunity in Otitis Media.

Authors:  Myung-Won You; Dokyoung Kim; Eun-Hye Lee; Dong-Choon Park; Jae-Min Lee; Dae-Woong Kang; Sang-Hoon Kim; Seung-Geun Yeo
Journal:  Int J Mol Sci       Date:  2022-02-21       Impact factor: 5.923

10.  A retrospective analysis of hearing after cholesteatoma surgery: the bony obliteration tympanoplasty versus canal wall up and canal wall down without mastoid obliteration.

Authors:  Hylke F E van der Toom; Marc P van der Schroeff; Mick Metselaar; Anne van Linge; Jantien L Vroegop; Robert J Pauw
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-04-10       Impact factor: 3.236

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.